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In 212 postmenopausal women with node-positive oestrogen receptor-positive (ERLBA) breast cancer subjected to radical surgery
and adjuvant tamoxifen, the risk of 6-year relapse increased with increasing values of intratumoral vascular endothelial growth factor
(VEGF) in patients whose tumours had a low/intermediate ERLBA content compared to patients with high-ERLBA tumours. These
findings indicate that tumour progression, activated or sustained by high VEGF levels, may be counteracted in high-ERLBA cancers by
tamoxifen, which in contrast fails to contrast the metastatic potential in low-ERLBA tumours.
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Breast tissue is highly responsive to changes in ovarian hormone
concentrations that induce a cyclic remodelling process involving
epithelial, stromal and vascular components during each menstru-
al cycle (Vogel et al, 1981). In particular, the angiogenic turnover is
regulated by oestrogens and progesterone, which modulate the
expression of vascular endothelial growth factor (VEGF) in the
epithelial cells of the terminal ductal–lobular units (Nakamura
et al, 1999).
Although the VEGF gene promoter lacks a perfect palindromic
oestrogen-responsive element, an analogue of the consensus
element that functions as a classical enhancer for oestrogen
receptor (ER) has been identified in the 30-untranslated region
(Hyder et al, 2000b).
Angiogenesis is known to represent a fundamental step in
tumour progression (Hanahan and Folkman, 1996) and clinical
evidence has shown that node-negative (N ) as well as node-
positive (Nþ) breast cancer patients with high intratumoral VEGF
concentrations have a significantly shorter relapse-free survival
(RFS) (Gasparini et al, 1997, 1999; Linderholm et al, 2000).
Preclinical studies on breast cancer cell lines demonstrated that,
as expected, oestrogens rapidly induce VEGF expression, which is
blocked by pure oestrogen antagonists (Ruohola et al, 1999; Hyder
et al, 2000a).
In a series of Nþ ER-positive (ERþ, by ligand-binding assay,
LBA) postmenopausal women with resectable breast cancer who
received adjuvant tamoxifen, we investigated the comprehensive
effect on RFS of VEGF content and steroid receptor profile,
evaluated in the same cytosolic fraction.
PATIENTS AND METHODS
Patients
The study included postmenopausal patients with primary
resectable invasive breast cancer, histologically classified as Nþ,
who underwent surgery at the Istituto Nazionale Tumori in Milan
between March 1991 and December 1995 and received only
adjuvant tamoxifen (20mgday
 1) for at least 2 years (median
duration time, 4 years) because of their positive ER status (ER
tumour concentration higher than 10fmolmg
 1 of protein). From
a total of 859 Nþ,E R þ postmenopausal patients, consecutive
with respect to steroid receptor determination at the time of
diagnosis, 289 were selected on the basis of treatment, histology
(pure or mixed ductal or lobular invasive tumours) and follow-up
(i.e. a minimum potential of 6 years from the date of surgery to the
date of last updating of patient records).
Of the 289 eligible patients, 212 (73%) were available for VEGF
evaluation. Their median age was 64 years (range, 50–85); 88
patients (42%) were treated by mastectomy and 124 (58%) by
breast-conserving surgery plus radiotherapy. All of them under-
went complete axillary lymph node dissection (median number of
examined nodes, 18). Most patients had one to three metastatic
axillary lymph nodes (139, 66%). Small (p2cm) and large
(42cm) tumours were equally represented (93, 48% and 99,
52%, respectively). After surgery, the patients were followed at 6-
month intervals during the first 5 years and at 12-month intervals
thereafter; disease status was assessed by means of physical
examination, chest X-ray, bone scan and abdominal sonography.
Treatment failure was defined as the first documented evidence of
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ynew disease manifestations in locoregional areas (seven cases),
distant sites (40 cases), or in the contralateral breast (five cases).
Relapse-free survival was calculated as the time elapsed from
diagnosis to the date of first recurrence or to the last clinical
examination for patients without documented disease manifesta-
tion. Median follow-up for the whole series was 68 months
(interquartile range, 52–82 months).
Steroid receptor determination by LBA
Steroid receptor content was determined according to the EORTC
recommendations and within national (Piffanelli et al, 1991) and
international (EORTC Breast cancer co-operative group, 1980)
quality control programmes by a double-labelling assay (Coradini
et al, 2000), and expressed as fmolmg
 1 of protein. Tumours with
an ERLBA concentration higher than 10fmolmg
 1 of protein were
defined as ERþ.
Vascular endothelial growth factor determination
The predominant VEGF isoform, VEGF65 (henceforward referred
to as VEGF), was measured by a quantitative enzyme immuno-
assay technique (Quantikine, human VEGF; R&D Systems,
Minneapolis, MN, USA) as described elsewhere (Coradini et al,
2001). Concentrations were expressed as pg of VEGF protein per
mg of total protein.
Statistical analysis
The overall association of VEGF level with patient age, tumour
size, number of metastatic lymph nodes, ERLBA and PgRLBA
content was evaluated by Spearman’s rank correlation coefficient.
The effect of VEGF, ERLBA and PgRLBA content on RFS was
investigated by multivariate analysis using a Cox regression model
in which also the number of metastatic lymph nodes was included.
All variables were considered on a continuous scale after
logarithmic transformation. Null values for PgRLBA content were
arbitrarily set at 1, taking a sensitivity threshold value of
2fmolmg
 1 of protein. According to a previous finding (Coradini
et al, 2001), linear terms for log(ERLBA), log(PgRLBA) and
log(VEGF) and the interaction between ERLBA and VEGF were
included in the model.
The proportional hazard assumption of the Cox model was
evaluated and the effect of model terms was tested as previously
reported (Coradini et al, 2001).
The library written by Harrell et al (1996) was applied in some
steps of the model building procedure and the SAS macro
programme RELIMPCR designed by Heinze and Schemper
(2001) was adopted for evaluation of the relative prognostic
contribution of the covariates.
RESULTS
In this series of ERLBA-positive tumours from postmenopausal
patients, the VEGF content ranged from 7 to 2186pgmg
 1 of
protein with 52, 95 and 200 as the 25th, 50th and 75th percentiles,
respectively; the PgRLBA concentration ranged from 1 to
2563fmolmg
 1 of protein with 40, 111 and 355 as the 25th, 50th
and 75th percentiles, respectively. Vascular endothelial growth
factor content did not show any significant correlation with any of
the other variables considered; estimated correlation coefficients
were all in the range 70.08.
In the multivariate model, the number of metastatic lymph
nodes, VEGF, ERLBA and the interaction between ERLBA and VEGF
were significantly related to prognosis (Table 1), whereas no
significant contribution was observed for PgRLBA. As for ERLBA,
VEGF and the ERLBA–VEGF interaction, the results were similar to
those previously obtained in patients with N– breast cancer who
did not receive systemic treatment (Coradini et al, 2001). This
finding further supports the role of ERLBA in modulating the
prognostic effect of VEGF and the negative interaction term
indicates a decrease in the unfavourable effect of VEGF for
increasing values of ERLBA.
To provide a description of the combined effect of VEGF and
ERLBA, the relative hazard (RH) for increasing VEGF concentra-
tions was plotted (Figure 1) for selected values of ERLBA (70 and
220fmolmg
 1 of protein) that were approximately equal to the 1st
and third quartiles of ERLBA distribution. Owing to the interaction
between ERLBA and VEGF, when the ERLBA content was set at
70fmolmg
 1 protein, the increase in the risk of disease recurrence
for high VEGF values associated with low ERLBA values was
evident. In fact, the estimated RH for patients with a VEGF content
of 200 vs those with a VEGF content of 50pgmg
 1 protein was 1.54
(95% CI, 1.07–2.20). Conversely, when the ERLBA content was set
at 220fmolmg
 1 protein, VEGF did not show any prognostic effect
and the estimated RH for the two selected values (200 and
50pgml
 1) was 0.89 (95% CI, 0.54–1.47).
Analysis of the prognostic contribution of the covariates showed
that the model explained only 13.2% of the total heterogeneity of
the relapse times of our case series and that, considering the
relative importance of prognostic factors, 8.2% was attributable to
the number of metastatic lymph nodes, whereas VEGF and ERLBA
together contributed with 3.3%, and PgR only with 0.8%.
DISCUSSION
According to the recently revised treatment guidelines for early
breast cancer (Goldhirsch et al, 2001), postmenopausal women
Table 1 Final Cox regression model results for RFS
Effect Wald statistics d.f. b
a P
Metastatic nodes 19.76 1 0.6054 o0.0001
VEGF 7.70
b 2 1.7562 0.0213
ERLBA 5.59
b 2 1.5317 0.0610
PgRLBA 1.26 1  0.0696 0.2617
ERLBA–VEGF 4.73 1  0.3405 0.0297
Total 30.78 6 o0.0001
aEstimated regression coefficient.
bFactor +interaction.
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Figure 1 Plots of the logarithm of the relative hazard of disease
recurrence as a function of VEGF level for different ERLBA values (fixed
approximately at the first and third quartiles of the distribution). The solid
line corresponds to an ERLBA¼70fmolmg
 1 protein, whereas the dashed
line corresponds to an ERLBA¼220fmolmg
 1 protein. Dotted lines
indicate 95% pointwise confidence limits (upper: UCL; lower: LCL).
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therapy with tamoxifen. However, a recent clinical study
(Linderholm et al, 2000) provided evidence that also the
intratumoral VEGF content could predict outcome following
adjuvant endocrine treatment: patients with ERþ tumours, but
a high VEGF expression, had a significantly shorter RFS and
overall survival. In agreement with these findings, our results
showed that, due to the presence of a negative interaction between
ERLBA and VEGF, already observed in a series of N  cancers
(Coradini et al, 2001), patients whose tumours had a low/
intermediate ERLBA content exhibited an increased risk of disease
recurrence with increasing values of intratumoral VEGF. Con-
versely, the VEGF level did not show prognostic effect in patients
whose tumours had a high ERLBA content. These findings suggest
that in tumours characterised by a high ERLBA concentration and
therefore more likely to be hormonally regulated, tumour
progression, activated or sustained by VEGF, may be counteracted
by the protective effect of endocrine therapy. Conversely, when a
patient has a high level of VEGF and a low ERLBA concentration,
tamoxifen could fail to contrast the tumour’s metastatic potential
and more tailored adjuvant treatment would be required including,
for example, an antiangiogenic agent.
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